USE OF GENE THERAPY TO INDUCE TRANSPLANT TOLERANCE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目的：针对终末期疾病患者的异种移植是解决人类器官供者短缺的一种潜在方法。人类拒绝来自猪捐赠者的移植，因为先前存在针对由α1，3-半乳糖基转移酶合成的半乳糖1，3半乳糖的天然异种抗体。这种酶在人类、猿类或东半球的猴子中不表达。因此，这些物种产生针对猪细胞上表达的半乳糖的异种抗体。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Xenograft transplantation for patients with end-stage diseases represents a potential solution to the shortage of human organ donors. Humans reject grafts from porcine donors due to pre-existing natural xenoantibodies directed at the gal alpha1,3gal carbohydrate which is synthesized by alpha1,3-galactosyltransferase. This enzyme is not expressed in humans, apes, or old world monkeys. These species, therefore, produce xenoantibodies directed at the gal carbohydrate which is expressed on pig cells.